Sens. Warn Colleagues Not To Derail FDA User Fee Bill

Law360, New York (March 29, 2012, 5:45 PM EDT) -- The drug and device industries on Thursday urged a Senate health panel to quickly approve their user fee agreements with the U.S. Food and Drug Administration, as the panel’s top members warned colleagues not to derail the bill with controversial amendments.

The user fee agreements, negotiated between the FDA and industry groups earlier this year, lay out how much drug and device companies must pay in fees to support the FDA review process. The agreements also establish performance goals for the FDA, for example shortening the...
To view the full article, register now.